Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:European_Union
|
| gptkbp:ATCCode |
L01DB16
|
| gptkbp:CASNumber |
144510-96-3
|
| gptkbp:chemicalFormula |
C22H28N6O2
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:developer |
Cell Therapeutics, Inc.
|
| gptkbp:genericName |
pixantrone
|
| https://www.w3.org/2000/01/rdf-schema#label |
Pixuvri
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
DNA intercalation
topoisomerase II inhibition |
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting alopecia infections neutropenia |
| gptkbp:usedFor |
leukemia
|
| gptkbp:bfsParent |
gptkb:Servier_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|